Login to Your Account



PART I: A COMPETITIVE SPACE

All eyes are on agents that target the PD-1 pathway

By Peter Winter
Editor

Monday, March 3, 2014

Although it has been predicted that this will be a lean year for the approval and launch of blockbuster drugs this picture could all change if any of the anti-programmed death-1 (PD-1) antibodies under development make it to market.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription